Jubilant Pharmova’s Shares Drop 6% Following 45% Year-on-Year Decline in Q1 Profits.

Jubilant Pharmova experienced significant market volatility following the release of its financial results for the first quarter of FY27, with shares declining nearly 6% to Rs 908 on BSE. The company’s consolidated profit plummeted 45% year-on-year (YoY), amounting to Rs 56 crore. This sharp decline was attributed to lower operating profitability coupled with increased depreciation expenses related to Line 3 in Spokane. Notably, while the profit figures revealed weakness, the total revenue for the quarter rose by 17% YoY, reaching Rs 2,229 crore, buoyed by strong performance across various business segments, particularly the CDMO Sterile Injectables division, which demonstrated robust growth driven by technology transfer revenues from new and operational lines.

In assessing the segmental performance, Radiopharmaceuticals recorded a revenue increase of 19% to Rs 322 crore, despite declining EBITDA margins due to unavailability of certain SPECT products. The company anticipates that these products will be back in the market by the second half of FY27, which could positively impact future revenues. The Allergy Immunotherapy sector also saw an 18% increase in revenues, underscoring the company’s position as a key supplier for Venom in the US, while the Drug Discovery business exhibited promising growth with an 8% revenue increase, reflecting operational resilience in the face of industry challenges.

Despite these positive revenue metrics, EBITDA figures were less encouraging, reflecting ongoing challenges. The CDMO Sterile Injectables segment, while growing, faced reduced margins due to increased operating expenses. Overall, total EBITDA for the quarter stood at Rs 268 crore, a figure that mirrors the pressing constraints from heightened remediation costs and a decrease in third-party revenues. As the company moves forward, it aims to launch multiple new products within FY27, which could play a pivotal role in mitigating current margin pressures and enhancing profitability.

Looking ahead, Jubilant Pharmova has set ambitious targets, delineating a vision to double its revenues from FY24 to FY30, with forecasts of EBITDA margins stabilizing between 23% to 25% by FY30. This forward-looking guidance, while optimistic, will necessitate careful execution in product development and operational efficiencies. Investors should closely monitor the company’s ability to navigate the competitive landscape and the successful implementation of upcoming product launches, which are critical to realizing its long-term growth objectives.

Source: The Economic Times

(Expert Note: This report was prepared by the Wealthova team.)